August 1, 2022Open Access
Sympathomodulation in Heart Failure with High vs. Normal Ejection Fraction
Resultado clave
Renal denervation demonstrated beneficial effects in patients with heart failure with normal and high ejection fraction, supporting further investigation of sympathomodulating treatments.
Diseño del estudio
Tipo
Observational
PICO estructurado
Does sympathomodulation using renal denervation alter pressure-volume relations in patients with HFpEF with high vs. normal ejection fraction?
P
Población
Patients with heart failure with preserved ejection fraction (HFpEF), categorized into high EF (EF > 60%, HEF) and normal EF (EF 50%-60%, NEF)
E
Exposición
Sympathomodulation using renal denervation (RDN)
O
Resultado
Alterations in pressure-volume relations using noninvasive single-beat estimationssurrogate
Renal denervation may offer beneficial sympathomodulatory effects in HFpEF patients across different ejection fraction ranges.
Resultado numérico
valor p: p=< 0.05
Resumen
Background: Despite recent advances in the treatment of heart failure with preserved ejection fraction (HFpEF), the overall outcome is poor and evidence-based therapeutic options are scarce. So far, the only evidence-based therapy in HFpEF, sodium glucose linked transporter 2 inhibitors, has only insignificant effects in patients with a high EF (EF > 60%, HEF) when compared to a normal EF (EF 50%-60%, NEF). This could be explained by different biomechanical and cellular phenotypes of HFpEF across the range of EFs rather than a uniform pathophysiology. We aimed to investigate the concept of different phenotypes in the HEF and NEF using noninvasive single-beat estimations and to observe alterations in pressure-volume relations in both groups following sympathomodulation using renal denervation (RDN). Methods: ). Results: < 0.05) but not in the HEF. Conclusions: Beneficial effects of RDN were observed in the NEF and HEF, supporting the further investigation of sympathomodulating treatments for HFpEF in future trials.